Prevalence of BRCA1 and BRCA2 mutations in Korean breast cancer patients

被引:33
作者
Ahn, SH
Hwang, UK
Kwak, BS
Yoon, HS
Ku, BK
Kang, HJ
Kim, JS
Ko, BK
Ko, CD
Yoon, KS
Cho, DY
Kim, JS
Son, BH
机构
[1] Univ Ulsan, Coll Med, Dept Surg, Seoul 138736, South Korea
[2] Asan Med Ctr, Seoul 138736, South Korea
[3] Eulji Univ, Sch Med, Dept Biochem & Mol Biol, Taejon, South Korea
[4] LabGenom Clin Res Inst, Yongin, South Korea
[5] Korea Univ, Dept Internal Med, Div Hematol Oncol, Seoul 136701, South Korea
关键词
breast neoplasms; genes; BRCA1; prevalence; Koreans;
D O I
10.3346/jkms.2004.19.2.269
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The incidence of breast cancer in Korea has been increasing in recent years, such that it is now the most common female cancer. Breast cancer in Korea is characterized by an earlier age of onset than in Western countries, suggesting that it would be related with genetic background. We assayed germline mutations in the BRCA genes to evaluate their genetic pathology in Korean breast cancer patients. The study subjects consisted of 173 patients at clinically higher risk and 109 unselected patients. Germline mutations in the entire coding sequences of the BRCA1 and BRCA2 genes were analyzed by Conformation-Sensitive Gel Electrophoresis (CSGE), and any aberrantly-sized band was sequenced. BRCA mutations were present in 12.7% of the high risk patients, compared with 2.8% of the unselected patients. Among high risk patients, mutations were most prevalent in patients with a family history of breast or first-degree ovarian cancer (22.1%), followed by those with male breast cancer (20%), bilateral breast cancer (20%), multiple organ cancer including breast (13%) and younger breast cancer patients (aged <35 yr) (8.1%). Moreover, BRCA mutations were detected in 34.8% of patients having two highr-risk factors. These findings suggest that BRCA gene mutation analysis should be performed on Korean patients with high-risk factors for breast cancer.
引用
收藏
页码:269 / 274
页数:6
相关论文
共 29 条
[11]  
Khoo Ui-Soon, 2002, Hum Mutat, V19, P307, DOI 10.1002/humu.9015
[12]   Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan [J].
Liede, A ;
Malik, IA ;
Aziz, Z ;
de los Rios, P ;
Kwan, E ;
Narod, SA .
AMERICAN JOURNAL OF HUMAN GENETICS, 2002, 71 (03) :595-606
[13]   Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer [J].
Loman, N ;
Johannsson, O ;
Kristoffersson, U ;
Olsson, H ;
Borg, Å .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (16) :1215-1223
[14]  
Malone KE, 2000, CANCER, V88, P1393, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1393::AID-CNCR17>3.0.CO
[15]  
2-P
[16]   BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines [J].
Matsuda, MLD ;
Liede, A ;
Kwan, E ;
Mapua, CA ;
Cutiongco, EMC ;
Borg, ATÅ ;
Narod, SA .
INTERNATIONAL JOURNAL OF CANCER, 2002, 98 (04) :596-603
[17]   A STRONG CANDIDATE FOR THE BREAST AND OVARIAN-CANCER SUSCEPTIBILITY GENE BRCA1 [J].
MIKI, Y ;
SWENSEN, J ;
SHATTUCKEIDENS, D ;
FUTREAL, PA ;
HARSHMAN, K ;
TAVTIGIAN, S ;
LIU, QY ;
COCHRAN, C ;
BENNETT, LM ;
DING, W ;
BELL, R ;
ROSENTHAL, J ;
HUSSEY, C ;
TRAN, T ;
MCCLURE, M ;
FRYE, C ;
HATTIER, T ;
PHELPS, R ;
HAUGENSTRANO, A ;
KATCHER, H ;
YAKUMO, K ;
GHOLAMI, Z ;
SHAFFER, D ;
STONE, S ;
BAYER, S ;
WRAY, C ;
BOGDEN, R ;
DAYANANTH, P ;
WARD, J ;
TONIN, P ;
NAROD, S ;
BRISTOW, PK ;
NORRIS, FH ;
HELVERING, L ;
MORRISON, P ;
ROSTECK, P ;
LAI, M ;
BARRETT, JC ;
LEWIS, C ;
NEUHAUSEN, S ;
CANNONALBRIGHT, L ;
GOLDGAR, D ;
WISEMAN, R ;
KAMB, A ;
SKOLNICK, MH .
SCIENCE, 1994, 266 (5182) :66-71
[18]  
*MIN HLTH WELF REP, 2003, ANN REP CANC REG PRO
[19]  
Neuhausen SL, 1999, CANCER-AM CANCER SOC, V86, P2575, DOI 10.1002/(SICI)1097-0142(19991201)86:11+<2575::AID-CNCR15>3.0.CO
[20]  
2-F